Skip to main content

CKC FUNDED RESEARCH

We fund innovative, first-of-its-kind research for pediatric cancer treatments because we believe that all children should not only survive, but thrive, after a cancer diagnosis. We’re committed to finding new and better ways to treat childhood cancer, and are confident that our approach to funding research is the key to increasing survivorship AND quality of life for kids fighting cancer.

Tanja Gruber

Stanford University

Improving Outcomes for KMT2A Rearranged Infants with ALL

Kathryn Lemberg

Johns Hopkins University

Targeting de novo pyrimidine biosynthesis in pediatric soft tissue sarcomas

Anya Levinson

University of California, San Francisco

Combination therapy using a novel Raf dimer inhibitor in pediatric AML

Amy Sexauer

Dana-Farber Cancer Institute

DHODH: A promising new target for the treatment of patients with T-ALL

Brian Tullius

Expansion Site for EXCEL Trial

Jennifer Kamens

Stanford University

Aberrant BER confers sensitivity to PARP Inhibitors in pediatric AML

Jonathan Metts

Moffitt Cancer Center, Johns Hopkins All Children’s Hospital

Tumor-Infiltrating Lymphocyte Therapy for High-Risk Solid Tumors

Theodore Johnson

Augusta University, Georgia Cancer Center

Extension of Pediatric Phase 2 Studies Using Indoximod with Chemotherapy and Radiation for Children with Advanced Brain Cancer

Joelle Straehla

Dana-Farber Cancer Institute

Dr. Joelle Straehla Young Investigator’s Grant at Dana-Farber Cancer Institute

James Geller

Cincinnati Children’s Hospital

Sodium Thiosulfate Otoprotection During Salvage Cisplatin Therapy

Elliot Stieglitz

University of California at San Fransisco, Benioff Children’s Hospital

A risk-stratified trial for newly diagnosed patients with juvenile myelomonocytic leukemia

Lena Winestone

University of California at San Fransisco, Benioff Children’s Hospital

Dr. Lena Winestone Young Investigator’s Grant at UCSF

Amy Smith

Arnold Palmer Hospital for Children

First Florida-Based Oncofertility Clinic for Childhood Cancer Patients

Jared Rowe

Dana-Farber Cancer Institute

Dr. Jared Rowe Young Investigator’s Grant at Dana-Farber Cancer Institute

Holly Meany

Children’s National Medical Center

Enhancing Tumor-Associated Antigen Cytotoxic T-Cell Immunotherapy in Patients with Relapsed/Refractory Wilms Tumor

Theodore Johnson

Augusta University, Georgia Cancer Center

Pediatric Phase 2 Studies Using Indoximod with Chemotherapy and Radiation for Children with Advanced Brain Cancer

Sabine Mueller

The University Children’s Hospital

Gregory Friedman

University of Alabama at Birmingham

Phase 1 Trial of Engineered HSV G207 in Children With

Schiehallion, at the Royal Hospital for Children

Expansion of Scotland Clinical Trial Accessibility

Michael Ortiz

Memorial Sloan Kettering Cancer Center

A multi-center phase I study of Codrituzumab (GC33, RG7686, RO5137382) in pediatric patients with relapsed or refractory GPC3 expressing solid tumors

Sandro Matosevic

Purdue University

Michael Ortiz

Memorial Sloan Kettering Cancer Center

Dr. Michael Ortiz Young Investigator’s Grant at Memorial Sloan Kettering Cancer Center

Thomas Cash

Emory University, Children’s Healthcare of Atlanta

AflacST1502: A Phase II Study of Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors

Cassie Kline-Nunnally – Transferred to Sabine Mueller

University of California at San Fransisco, Benioff Children’s Hospital

A Target Validation Study of Fimepinostat in Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG), Recurrent Medulloblastoma, or Recurrent High-Grade Glioma (HGG)

Kenneth A Alexander

Nemours Children’s Hospital

Treatment of Hepatoblastoma with the Zika Virus

Elizabeth Beierle

University of Alabama at Birmingham

The Role of PIM3 Protein in Hepatoblastoma Resistance to Chemotherapy

Brenda Gibson

Schiehallion, at the Royal Hospital for Children

Scotland Clinical Trial Accessibility Grant

David Munn

Augusta University, Georgia Cancer Center

Support to Develop Indoximod Trial at Augusta University

Sabine Mueller

University of California at San Fransisco, Benioff Children’s Hospital

Phase 1 Feasibility Trial of Repeated Convection Enhanced Delivery of HDAC Inhibitor MTX110 (Panobinostat) under real time image guidance for the Treatment of Children with Malignant Midline Gliomas

Cassie Kline-Nunnally

University of California at San Fransisco, Benioff Children’s Hospital

Dr. Cassie Kline Young Investigator’s Grant at UCSF

Gregory Friedman

University of Alabama at Birmingham

Phase I Clinical Trial of HSV G207 Alone or With a Single Radiation Dose in Children With Recurrent Supratentorial Brain Tumors

Giselle Sholler

Helen DeVos Children’s Hospital, Spectrum Health

A Phase I/II Trial of DFMO in Combination With Bortezomib in Patients With Relapsed or Refractory Neuroblastoma

Mario Otto

University of Wisconsin-Madison Carbone Cancer Center

TCR-αβ+ and CD19+ Depleted KIR/KIR Ligand-mismatched Haploidentical Hematopoietic Stem Cell Transplant and Zoledronate for Pediatric Relapsed/Refractory Hematologic Malignancies and High Risk Solid Tumors

Theodore Johnson

Augusta University, Georgia Cancer Center

Phase 1 Feasibility Trial of Repeated Convection Enhanced Delivery of HDAC Inhibitor MTX110 (Panobinostat) under real time image guidance for the Treatment of Children with Malignant Midline Gliomas

Theodore Johnson

Augusta University, Georgia Cancer Center

A Phase I Trial of Indoximod and Temozolomide-Based Therapy for Children With Progressive Primary Brain Tumors

Join the fight against
Pediatric cancer

It takes all of us working together to create better treatments for kids.

Get Involved Today

Are you a
researcher

Learn more about CKc’s grant cycle.

How to apply for a research grant